Immediate Impact
1 from Science/Nature 51 standout
Citing Papers
Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer
2024 Standout
Cancer statistics, 2024
2024 Standout
Works of Thomas Kegel being referenced
e8a2 BCR–ABL: more frequent than other atypical BCR–ABL variants?
2005
Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers
2004
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Thomas Kegel | 179 | 68 | 62 | 78 | 74 | 36 | 385 | |
| Marin Nola | 98 | 86 | 38 | 50 | 51 | 30 | 371 | |
| Peter S. Kennedy | 135 | 45 | 140 | 91 | 37 | 26 | 390 | |
| Katerina Stefanaki | 116 | 37 | 26 | 45 | 66 | 28 | 357 | |
| Yehudith Ben‐Arieh | 88 | 35 | 121 | 103 | 80 | 29 | 435 | |
| Hande Turna | 170 | 32 | 152 | 76 | 92 | 50 | 425 | |
| Naomi Katsuki | 102 | 52 | 167 | 146 | 73 | 29 | 384 | |
| Farid Kosari | 164 | 70 | 35 | 41 | 75 | 37 | 441 | |
| M. Crump | 176 | 120 | 118 | 79 | 43 | 20 | 453 | |
| Kouichi Isobe | 127 | 114 | 105 | 71 | 61 | 29 | 423 | |
| Philip J. Daroca | 82 | 32 | 135 | 135 | 43 | 37 | 364 |
All Works
Loading papers...